Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/acr.24457 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recent advances in the diagnosis and therapy of large vessel vasculitis.
Pol Arch Intern Med
June 2022
Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Altınbas University, Bahcelievler MedicalPark Hospital, Istanbul, Turkey
Large vessel vasculitis (LVV), including Takayasu arteritis (TAK) and giant cell arteritis (GCA), causes granulomatous vascular inflammation mainly in large vessels, and is the most common primary vasculitis in adults. Vascular inflammation may evoke many clinical features including vision impairment, stroke, limb ischemia, and aortic aneurysms. The best way to diagnose LVV is to combine medical history, physical examination, various laboratory tests, and imaging modalities.
View Article and Find Full Text PDFTreatment of Giant Cell Arteritis (GCA).
J Clin Med
March 2022
Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Systémiques Rares d'Ile de France, APHP-CUP, Hôpital Cochin, F-75014 Paris, France.
Giant cell arteritis (GCA) is the most frequent primary large-vessel vasculitis in individuals older than 50. Glucocorticoids (GCs) are considered the cornerstone of treatment. GC therapy is usually tapered over months according to clinical symptoms and inflammatory marker levels.
View Article and Find Full Text PDFAdvances in the Treatment of Giant Cell Arteritis.
J Clin Med
March 2022
Department of Rheumatology, Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain.
Giant cell arteritis (GCA) is the most common vasculitis among elderly people. The clinical spectrum of the disease is heterogeneous, with a classic/cranial phenotype, and another extracranial or large vessel phenotype as the two more characteristic patterns. Permanent visual loss is the main short-term complication.
View Article and Find Full Text PDFGiant cell arteritis: what is new in the preclinical and early clinical development pipeline?
Expert Opin Investig Drugs
September 2022
Department of Rheumatology, St. James's Hospital, Dublin, Republic of Ireland.
Introduction: Giant Cell Arteritis (GCA) is the most common systemic vasculitis worldwide. For decades, glucocorticoids have represented the mainstay of treatment, at the expense of toxic systemic effects owing to prolonged courses of high-dose treatment regimens. The search for effective drugs permitting lower glucocorticoid treatment regimens in GCA has been afrustrating one.
View Article and Find Full Text PDFVasculitis therapy refines vasculitis mechanistic classification.
Autoimmun Rev
June 2021
Department of Biomedicine, Aarhus University, Aarhus, Denmark; Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark; Department of Rheumatology, Silkeborg Regional Hospital, Silkeborg, Denmark. Electronic address:
Article Synopsis
- The primary vasculitides are a diverse group of immune-related diseases categorized by the size of the affected blood vessels, with recent studies exploring more specific immunological mechanisms.
- A systematic review of 40 studies revealed the efficacy of various biologic therapies, such as tocilizumab for large vessel vasculitis and rituximab for granulomatosis with polyangiitis and microscopic polyangiitis.
- Findings indicate that targeting specific cytokines and cellular mechanisms can help refine the classification of vasculitis and may lead to distinct treatment approaches based on disease subtype.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!